Anokion - Crunchbase Company Profile & Funding

Q: Where is Anokion's headquarters?

Anokion is located in Ecublens, Vaud, Switzerland.

Q: Who invested in Anokion?

Anokion has 8 investors including Pfizer Breakthrough Growth Initiative And Versant Ventures.

Q: When was the last funding round for Anokion?

Anokion closed its last funding round on obfuscated from a Venture - Series Unknown round.

Overview

Anokion

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Anokion

CB Rank

104296

Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.

Acquired by

Celgene

Founded

obfuscation

Private

Venture - Series Unknown

Ecublens, Vaud, Switzerland

11-50

anokion.com/

Biotechnology

Clinical Trials

Therapeutics

Funding Rounds

Venture - Series Unknown

OBF

obfuscation

Series B

OBF

obfuscation

Series A

OBF

obfuscation

Key People

Carlo Rizzuto: Chief Business Officer
Past Role: Novartis, Global Program Team Director
Raj Manchanda: Chief Development Officer (CDO)
Past Role: Frequency Therapeutics, Senior Vice President, Drug Development and Technical Operations

Details

Legal Name

Anokion SA

Operating Status

Active

Company Type

For Profit

Founders

Jeffrey A. Hubbell, Kristen M. Lorentz, Melody Swartz, Oscar Buset, Stephan Kontos

About the Company

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be

translated to virtually any protein in numerous clinical indications.

Contact Email

info@anokion.com

Predictions & Insights

Growth Insight

See this Growth Insight

Anokion is

Lorem

to be growing

Top Contributing Factors

Headcount Reduction

Growth Prediction

See this Growth Prediction

Products & Services

KAN-101

An experimental therapy in clinical development for treating celiac disease by targeting disease-causing antigens to induce immune tolerance.

ANK-700

A therapeutic candidate in development for relapsing-remitting multiple sclerosis designed to modulate autoreactive immune cells via antigen-specific immune tolerance.

Research & Development

Anokion is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Anokion	1	obfuscated obfuscation	Pfizer Breakthrough Growth Initiative	Venture - Series Unknown

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Pfizer Breakthrough Growth Initiative	Yes	Venture Round - Anokion	Allison J Kean, MD
Pfizer Breakthrough Growth Initiative	Yes	Venture Round - Anokion	Allison J Kean, MD
Pfizer Breakthrough Growth Initiative	Yes	Venture Round - Anokion	Allison J Kean, MD
Pfizer Breakthrough Growth Initiative	Yes	Venture Round - Anokion	Allison J Kean, MD
Pfizer Breakthrough Growth Initiative	Yes	Venture Round - Anokion	Allison J Kean, MD